Phytotum Vinaigre RENOUVEAU FEMININ
Food supplement declared in France, decision dated 22 December 2025
Phytotum Vinaigre RENOUVEAU FEMININ, from HELENE FLECHET, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Medicago sativa 2.25 g per day, Rosmarinus officinalis 2 g per day, Salvia officinalis 0.85 g per day, Vinaigre de cidre. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- Phytotum
- Food business operator placing the product on the market
- HELENE FLECHET
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Autre : vinaigre de plantes
- Daily dose
- 30 ml
- Directions for use
- 2 cuillères à soupe par jour au repas, dilué dans l'eau ou dans l'huile
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, History of breast cancer, Pregnant women
- Objectives stated by the manufacturer (these are not authorised claims)
- Menopause
Declaration 350722, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Medicago sativa L. | Leaf | Other macerate | 2.25 g |
| Rosmarinus officinalis L. | Leaf | Other macerate | 2 g |
| Salvia officinalis L. | Leaf | Other macerate | 0.85 g |
Other active ingredients
| Name | Per day |
|---|---|
| Vinaigre de cidre | not declared |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne remplace pas un traitement médical approprié Ne se substitue pas à une alimentation variée et un mode de vie sain Tenir hors de portée des jeunes enfants Ne pas dépasser la dose journalière recommandée (30 ml) Déconseillé aux enfants de moins de 12 ans et aux femmes enceintes ou allaitantes Déconseillé chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein Déconseillé en cas d’obstruction biliaire ou d’autres troubles de la fonction biliaire Faire une pause d'1 semaine toutes les 3 semaines Agiter avant emploi Conserver au frigo
Regulatory points
- Legal conditions
Medicago sativa L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Medicago sativa L.
Read the warning, when it applies and the studies cited
ALFALFA - MEDICAGO SATIVA
Route of administration: Oral
Cautions and warnings
Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Condition of application: All products.
Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.
Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- Rosmarinus officinalis L.
Read the warning, when it applies and the studies cited
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Route of administration: Oral (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Health Canada monograph dated 29 May 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Route of administration: Topical (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
Sources cited by Health Canada (1)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Salvia officinalis L.
Read the warning, when it applies and the studies cited
SAGE - SALVIA OFFICINALIS - Buccal
Cautions and warnings
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Health Canada monograph dated 28 March 2025
SAGE -SALVIA OFFICINALIS Oral
Cautions and warnings
Condition of application: Carminative, Diaphoretic, Antihidrotic, Antigalactagogue.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Condition of application: All products.
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).
Sources cited by Health Canada (3)
- Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Do not use if you have a seizure disorder such as epilepsy (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).
Sources cited by Health Canada (3)
- Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Phytotum Vinaigre RENOUVEAU FEMININ Phytotum, earlier declaration, replaced by the 2025 declaration : different composition: 1 ingredient(s) added, 1 missing
Brand : Phytotum
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Phytotum Vinaigre RENOUVEAU FEMININ: composition and regulation”, https://compoatlas.com/en/supplements/products/350722-phytotum-vinaigre-renouveau-feminin, updated 15 November 2026.